Redefining TCRm Safety with ValidaTe

ValidaTe just gave the answer to one of the hardest problems in TCRm-based immunotherapy: how to systematically predict and eliminate off-target toxicity before it kills the program in the clinic.

EpiTox: completing our Validate platform for TCR-mimic antibody development

With the publication of EpiTox, all three components of our ValidaTe platform are now publicly validated and available.

EpiPredict: ML-powered identification of pHLA off-targets for TCR-mimic antibodies

EpiPredict delivers a new level of confidence for safety assessment in TCR like drug modalities and provides a powerful solution for developers of T cell receptor mimic (TCRm) antibodies.

Ranked among Germany’s biotech pioneers of the coming decade

WirtschaftsWoche has selected Matthias Wiedenfels as a winner of “Germany’s 30 by 2030”